|
CASA-Q score
|
51 (35–70)
|
34 (29–40)
|
< 0.05
|
|
Nocturnal cough
|
7 (58%)
|
6 (38%)
|
1.00
|
|
mMRC score
| | | |
|
≥ 1
|
7 (58%)
|
8 (50%)
|
0.72
|
|
≥ 2
|
5 (42%)
|
0 (0%)
|
< 0.05
|
|
Nasal obstruction
|
6 (50%)
|
2 (13%)
|
0.09
|
|
Pulmonary exacerbations
|
1 (0–2)
|
1 (0–2)
|
0.64
|
|
Number per year
| | | |
|
Number over last 3 months
|
1 (0–1)
|
0 (0–1)
|
0.78
|
|
At least 1 exacerbation in the past year
|
6 (50%)
|
10 (62%)
|
0.70
|
|
At least 1 exacerbation in the past 3 months
|
6 (50%)
|
7 (44%)
|
1.00
|
|
At least 1 antibiotic use in the past year
|
4 (33%)
|
2 (13%)
|
0.35
|
|
Bacterial colonization of the airways (n = 27)
| | | |
|
Pseudomonas aeruginosa
|
3 (25%)
|
11(69%)
|
0.24
|
|
Burkholderia cepacia
|
0 (0%)
|
0 (0%)
|
1.00
|
|
Stenotrophomonas maltophilia
|
1 (8%)
|
0 (0%)
|
0.44
|
|
Achromobacter xylosoxidans
|
0 (0%)
|
0 (0%)
|
1.00
|
|
Pulmonary function tests
| | | |
|
FEV1 (mL)
|
2885 (1470–3490)
|
2065 (1540–4030)
|
0.93
|
|
FEV1 (% predicted)
|
74 (40–108)
|
66 (38–89)
|
0.42
|
|
FVC (mL)
|
3945 (2720–4435)
|
3530 (2680–5100)
|
1.00
|
|
FVC (% predicted)
|
97 (65–113)
|
86 (65–97)
|
0.22
|
|
FEV1/FVC
|
64 (55–82)
|
69 (53–74)
|
0.70
|
|
6 MWT (n = 16)
| | | |
|
SpO2 min (%)
|
93 (91–96)
|
96 (93–97)
|
0.25
|
|
Distance (m)
|
496 (425–584)
|
581 (505–630)
|
0.21
|
